Longeveron (LGVN) Short term Debt (2021 - 2023)

Longeveron (LGVN) posted quarterly Short term Debt of $586000.0 for Q3 2023, up 1.38% quarter-over-quarter from $578000.0 in Q2 2023.

Longeveron (LGVN) Short term Debt (2021 - 2023) Analysis & Trends

Longeveron's Short term Debt history runs 3 years deep, the most recent figure standing at $586000.0 for Q3 2023.

In Q3 2023, Short term Debt changed N/A year-over-year to $586000.0; the TTM figure through Sep 2023 stood at $586000.0 (changed N/A YoY), while the FY2022 annual figure was $564000.0, up 5.03% from the prior year.
Short term Debt for Q3 2023 stood at $586000.0, up from $578000.0 in the prior quarter.
The five-year high for Short term Debt was $586000.0 in Q3 2023, with the low at $537000.0 in Q4 2021.
The 3-year median for Short term Debt is $571000.0 (2023), against an average of $567200.0.
Peak annual rise in Short term Debt reached 5.03% in 2022, while the deepest fall reached 5.03% in 2022.
Longeveron's Short term Debt stood at $537000.0 in 2021, then gained by 5.03% to $564000.0 in 2022, then gained by 3.9% to $586000.0 in 2023.
Business Quant data shows LGVN's Short term Debt at $586000.0 in Q3 2023, $578000.0 in Q2 2023, and $571000.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Longeveron	26.51 Mn	16.41 Mn	182,000.00

Download Data